Investigating The Role of Inflammatory Markers at Admission in Defining the Severity of Moderate-to-Critical COVID-19: A Cross-Sectional Analysis.
C-reactive protein
COVID-19
Ferritin levels
Inflammatory markers
Lactate dehydrogenase
Journal
Journal of community hospital internal medicine perspectives
ISSN: 2000-9666
Titre abrégé: J Community Hosp Intern Med Perspect
Pays: United States
ID NLM: 101601396
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
06
2021
revised:
26
01
2022
accepted:
01
02
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
The spectrum of Coronavirus disease-2019 (COVID-19) has been clinically defined from asymptomatic carriers to critical illness. Different inflammatory markers have been used to account for the severity and outcomes of this disease in different settings. Our study aims to investigate the role of these inflammatory markers in defining COVID-19 severity. This cross-sectional study included 200 confirmed cases of COVID-19. Inflammatory markers including lymphocyte count, D-Dimers, Ferritin, CRP, LDH were noted at admission. The moderate-to-critical disease was defined according to the WHO criteria. Descriptive statistics were applied. Mann-Whitney U-test was applied to compare the difference of markers between moderate-severe and critical patients. ROC was plotted to determine the cut-off values of these markers. Binary logistics regression analysis was used to assess which markers significantly predict the severity of COVID-19. A D-dimer value of >775 ng/ml and LDH >495 U/L had a sensitivity of 72.9% and 79.2% and specificity of 57.9% and 53.6% respectively for critical COVID-19 illness. CRP levels of >100.5 mg/dl has a sensitivity of 66.7%. All inflammatory markers were significantly higher in a critical group of patients (p < 0.05) except for lymphopenia. Binary logistics regression analysis shows that LDH levels and D-dimers were only significant predictors of severity in COVID-19 patients. Inflammatory markers at admission are very useful in defining the severity of COVID-19 in addition to the clinical criteria. This is also useful in predicting adverse outcomes.
Sections du résumé
Background and aims
UNASSIGNED
The spectrum of Coronavirus disease-2019 (COVID-19) has been clinically defined from asymptomatic carriers to critical illness. Different inflammatory markers have been used to account for the severity and outcomes of this disease in different settings. Our study aims to investigate the role of these inflammatory markers in defining COVID-19 severity.
Methods
UNASSIGNED
This cross-sectional study included 200 confirmed cases of COVID-19. Inflammatory markers including lymphocyte count, D-Dimers, Ferritin, CRP, LDH were noted at admission. The moderate-to-critical disease was defined according to the WHO criteria. Descriptive statistics were applied. Mann-Whitney U-test was applied to compare the difference of markers between moderate-severe and critical patients. ROC was plotted to determine the cut-off values of these markers. Binary logistics regression analysis was used to assess which markers significantly predict the severity of COVID-19.
Results
UNASSIGNED
A D-dimer value of >775 ng/ml and LDH >495 U/L had a sensitivity of 72.9% and 79.2% and specificity of 57.9% and 53.6% respectively for critical COVID-19 illness. CRP levels of >100.5 mg/dl has a sensitivity of 66.7%. All inflammatory markers were significantly higher in a critical group of patients (p < 0.05) except for lymphopenia. Binary logistics regression analysis shows that LDH levels and D-dimers were only significant predictors of severity in COVID-19 patients.
Conclusion
UNASSIGNED
Inflammatory markers at admission are very useful in defining the severity of COVID-19 in addition to the clinical criteria. This is also useful in predicting adverse outcomes.
Identifiants
pubmed: 35712690
doi: 10.55729/2000-9666.1029
pii: jchimp-12-02-001
pmc: PMC9195063
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-5Informations de copyright
© 2022 Greater Baltimore Medical Center.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that there is no conflict of interest.
Références
J Community Hosp Intern Med Perspect. 2020 Sep 03;10(5):402-408
pubmed: 33235672
World J Emerg Surg. 2021 Mar 8;16(1):9
pubmed: 33685484
Clin Chim Acta. 2020 Oct;509:135-138
pubmed: 32531257
Cureus. 2020 Sep 11;12(9):e10383
pubmed: 33062504
Int J Lab Hematol. 2020 Dec;42(6):761-765
pubmed: 32779838
PLoS One. 2021 Mar 30;16(3):e0249421
pubmed: 33784355
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Int J Infect Dis. 2020 Jun;95:304-307
pubmed: 32344011
J Intensive Care. 2020 Jul 10;8:49
pubmed: 32665858
ERJ Open Res. 2020 Jul 13;6(2):
pubmed: 32685436
Respir Res. 2020 Aug 27;21(1):224
pubmed: 32854739
Aging (Albany NY). 2020 Jun 24;12(12):11245-11258
pubmed: 32633729
Exp Biol Med (Maywood). 2020 Sep;245(15):1368-1375
pubmed: 32635752
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Coll Physicians Surg Pak. 2020 Oct;30(10):158-163
pubmed: 33291195
Cureus. 2021 Jan 21;13(1):e12832
pubmed: 33633875